This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Fox, H. C. Articles by Turner, J. J. D. Search for Related Content PubMed PubMed Citation Articles by Fox, H. C. Articles by Turner, J. J. D. Social Bookmarking                         What's this?

Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug

Department of Psychology, University of East London, Romford Road London, E15 4LZ, UK h.c.fox{at}uel.ac.uk

A. C. Parrott

J. J. D. Turner

Department of Psychology, University of East London, London, UK

Previous research has shown drug-free Ecstasy users to demonstrate selective cognitive impairment However, there seems to be a degree of individual variation in the occurrence of such deficits. The present study aimed to assess whether these cognitive deficits are related to an awareness of problematic Ecstasy use, or to past drug dosage. Twenty regular Ecstasy users who reported experiencing Ecstasy-related problems were compared with 20 Ecstasy users who had not reported any previous problems. The two groups displayed similar past histories in relation to a range of illicit drugs, and were divided into low, medium and high users. The controls comprised 20 illicit recreational drug users who had never taken Ecstasy. Executive task measures comprised the Tower of London (TOL), the Wisconsin Card Sorting Task (WCST) and spatial working memory. Immediate and delayed word recall, matched verbal recognition and recall and simple reaction time were also included. Both Ecstasy groups performed significantly worse than controls on two executive measures: TOL planning time and spatial working memory score. There were no differences in cognitive impairment between the Ecstasy users who complained of problems and those who did not. In both groups, decrement on executive tasks was demonstrated as a function of previous drug dose. The study confirms that heavy Ecstasy polydrug use may culminate in selective executive deficits. It also demonstrates that two differently self-perceived Ecstasy groups showed similar cognitive impairment, despite only one group complaining of problems. Because all Ecstasy participants also consumed a range of other illicit drugs, the results are reflective of Ecstasy polydrug use in individuals who use Ecstasy as a drug of preference.

Key Words: drug use problems • executive • neurotoxicity • MDMA • memory • serotonin

Journal of Psychopharmacology, Vol. 15, No. 4, 273-281 (2001)
DOI: 10.1177/026988110101500406


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. B. Quednow, F. Jessen, K.-U. Kuhn, W. Maier, I. Daum, and M. Wagner Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction J Psychopharmacol, May 1, 2006; 20(3): 373 - 384. [Abstract] [PDF]

				K. Soar, J. J. D. Turner, and A. C. Parrott Problematic versus non-problematic ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors J Psychopharmacol, May 1, 2006; 20(3): 417 - 424. [Abstract] [PDF]

				J. Rodgers, T. Buchanan, C. Pearson, A. C. Parrott, J. Ling, T. Heffernan, and A. B. Scholey Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study J Psychopharmacol, May 1, 2006; 20(3): 437 - 446. [Abstract] [PDF]

				A. C. Parrott and C. A. Marsden MDMA (3,4-methylenedioxymethamphetamine) or ecstasy: the contemporary human and animal research perspective J Psychopharmacol, March 1, 2006; 20(2): 143 - 146. [PDF]

				A. C. Parrott MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress J Psychopharmacol, March 1, 2006; 20(2): 147 - 163. [Abstract] [PDF]

				E. Gouzoulis-Mayfrank and J. Daumann The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview J Psychopharmacol, March 1, 2006; 20(2): 188 - 193. [Abstract] [PDF]

				N. Easton and C. A. Marsden Ecstasy: Are animal data consistent between species and can they translate to humans? J Psychopharmacol, March 1, 2006; 20(2): 194 - 210. [Abstract] [PDF]

				A. C. Parrott Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy J Psychopharmacol, January 1, 2005; 19(1): 71 - 83. [Abstract] [PDF]

				J. Rodgers, T. Buchanan, A. B. Scholey, T. M. Heffernan, J. Ling, and A. C. Parrott Patterns of Drug Use and the Influence of Gender on Self-Reports of Memory Ability in Ecstasy Users: A Web-Based Study J Psychopharmacol, December 1, 2003; 17(4): 389 - 396. [Abstract] [PDF]

				A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508. [Abstract] [Full Text] [PDF]

				J. C. Cole, H. R. Sumnall, and G. F. Wagstaff What is a dose of ecstasy? J Psychopharmacol, March 1, 2002; 16(2): 189 - 190. [PDF]